IDO/TDO expressions can be altered by these microenvironment factors for the development of targeted therapeutics, comprehending how the dynamic changes in the tumor microenvironment affect immune responses and the effectiveness of IDO/TDO inhibitors (Rohrig et al., 2015). This evidence concerns the gene TDO2 and neoplasm.